Eikon Therapeutics announced it will present six abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing progress in its clinical-stage cancer drug programs. The presentations include updated trial data for EIK1001 (targeting lung cancer and melanoma), EIK1003 (a PARP1 inhibitor for various solid tumors), and EIK1005 (a WRN inhibitor for tumors with DNA replication issues). These updates highlight Eikon's efforts to develop novel therapies for advanced cancers, with ongoing studies exploring both monotherapy and combination treatments. The data presentations aim to inform future patient selection and treatment strategies, supporting potential drug registrations.
At Google Next 2026, Google Cloud Security used Instruqt's hands-on platform to train over 150 practitioners on Agentic AI capabilities. Participants built their own AI agents in dedicated Google Cloud Vertex AI environments, gaining practical experi...
First Trust S&P REIT Index Fund (FRI) saw its 2025 distribution fall to $0.8155 per share from $0.9104 in 2024, reflecting higher financing costs amid rising 10-year Treasury yields. The fund tracks the S&P U.S. REIT Index and holds diversified, larg...
The Vanguard S&P 500 Value Index Fund ETF (VOOV) provides income through dividends from value stocks in the S&P 500, with payouts having roughly doubled over the past decade. Its income mainly comes from sectors like Information Technology, Financial...
The iShares Select Dividend ETF (DVY) provides a reliable income stream with a trailing yield of about 3.5%, sourced from dividends of roughly 100 U.S. companies known for stable payouts. Its portfolio focuses on defensive sectors like utilities, fin...
Reddit, Inc. has seen its stock price retrace after initial excitement over AI and user growth diminished. The company reported a modest 7% year-over-year increase in logged-in users for Q1 2026, with key U.S. user growth under 10%. While Reddit's po...
